



*Building a leading specialty pharmaceutical company*

**Knight Therapeutics Inc.**  
**(TSX: GUD)**

*Investor presentation*  
*November 2025*



# Forward Looking Statements

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024 as filed on [www.sedarplus.ca](http://www.sedarplus.ca). Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.



# Knight Overview

Knight is a multinational specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America with over 150 products and over 20 partners

- **Since founding in February 2014**
  - Raised \$685M at increasing valuations (\$3.50 - \$10.00)
  - Deployed or committed to deploy **\$1.2B of capital, to date**
  - Acquired Grupo Biotoscana, a specialty pharmaceutical company with presence across Latin America
  - Closed Paladin and Sumitomo transactions in June 2025
- **TTM - Q3-25 Financial Highlights**
  - Revenue of \$414M
  - Generated cashflow from operations of \$36M
- **TTM - Q3-25 Non-GAAP measures**
  - Adjusted Revenue<sup>1</sup> of \$413M - growth of 15% compared to TTM prior year
  - Adjusted EBITDA<sup>1</sup> of \$64M - an increase of 16% compared to TTM prior year
  - Adjusted EBITDA per share<sup>1</sup> \$0.64 - an increase of 19% compared to prior year
- **Over the last 5 years:**
  - Knight has entered into **16 agreements** for **63 products** and invested over **\$425M**
    - Current pipeline expected to generate over \$200M of revenues
  - Invested over \$250M in buyback of shares and acquired 31% of shares outstanding

# Our Growth Strategies

## Product Portfolio

- 1 In-license late-stage prescription pharmaceuticals
- 2 Acquire mature or “under-promoted” products from Big Pharma
- 3 Develop near-term, low risk / low expense products




## M&A

- 4 Bolt-on acquisitions of portfolios or companies to complement our current business




# Our Footprint

Adjusted Revenue<sup>1,2</sup> by Geography



Headcount<sup>3</sup> by Geography



- Knight Affiliates
- Knight Distributors



~ \$414M in Revenue<sup>1</sup> and Adjusted Revenue<sup>1,2</sup>



11 Countries + distributors in Central America and Caribbean



+800 Employees



+150 Products  
>25 Pipeline & early launch products



+20 Partners



2 Manufacturing Plants  
1 R&D Center  
1 Regional Distribution Center

<sup>1</sup> Trailing twelve months ended September 30, 2025

<sup>2</sup> Adjusted Revenues and Adjusted EBITDA are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section 8 — Financial Results under Non-GAAP measures in the Management Analysis & Discussion for additional details.

<sup>3</sup> Headcount as at October 15, 2025



# Paladin and Sumitomo Transactions

Growing Canada to top revenue contributor in 2 years

## Paladin Transaction

- Asset purchase agreement to acquire Paladin
- In June 2025, at closing, paid \$85M + \$22M for inventory, and potential contingent milestones of US\$15M
- Payment at closing had a holdback of \$15M that may be released upon certain conditions, of which \$5M released

## Paladin Business

- Reported revenues of \$70M<sup>1</sup> in 2024
- Portfolio of over 40 products
  - Includes owned mature and in-licensed products
  - Promoted portfolio includes products in neurology and specialty hospital products
  - Most recent launch was Xcopri® for treatment of epilepsy
  - Pipeline includes Wyzora® for the treatment of plaque psoriasis

## Paladin Products



## Sumitomo Transaction

- Entered into: (1) an exclusive Canadian license and supply agreements for Myfembree®, Orgovyx® and vibegron, and, (2) an asset purchase agreement to acquire certain mature products.
- Upfront payment amount of \$25.4M and potential contingent milestones of up to \$15.75M

## Sumitomo Portfolio

- Licensed products generated revenues of \$11.2M for the TTM ended March 2025
- Portfolio of 6 products
  - Includes mature and in-licensed products
  - Promoted portfolio includes products in neurology and specialty hospital products
  - Most recent launch was Myfembree® for treatment of both heavy menstrual bleeding and endometriosis, and Orgovyx® for treatment of advanced prostate cancer
  - Pipeline includes vibegron for the treatment of overactive bladder (OAB)

## Sumitomo Products




<sup>1</sup> Excludes products that Paladin has stopped selling or is in the process of discontinuing.



# Our Market

Pan-American (ex US) market represents ~6% of global pharmaceutical market

## Market Size at Constant Currencies<sup>1</sup>



<sup>1</sup> Source: Country IQVIA Audits, \* 2024 = MAT Jan 2025 except BRA (MAT Feb 2025), BOL Retail (MAT Dec 2024), ARG Non-retail (MAT Dec 2024), CEA Non-retail (MAT Nov 2024) and COL non-retail (MAT Sep 2024).

<sup>2</sup> Constant Exchange rates used for Argentina (CCL) 1,207.00; Bolivia 6.91; Brazil 5.77; Chile 1,000.20; Colombia 4,295.53; Dominican Republic 61.39; Ecuador 1.00; Mexico 20.58; Peru 3.75; Paraguay 7,874.02; Uruguay 43.79; Central America and Venezuela based on variable exchange rates. CEA=CEA + DOM; URU=UMU+URY; \*\*Growth rates exclude COVID Vaccines


<sup>3</sup> CAGR represents the compound annual growth rate which is calculated as the (2024 divided by the 2020 market size)<sup>(1 divided by the number of years)-1</sup>.




# Our Portfolio

Innovative Promoted products: 73% of TTM Q3-2025 sales, delivered growth of 14% & 3-year CAGR of 29%

ADJUSTED REVENUE<sup>1,2</sup> BY PRODUCT PORTFOLIO



ADJUSTED REVENUE<sup>1,2</sup> BY THERAPEUTIC AREA



## KEY PRODUCTS\*

### Oncology and Hematology



### Infectious Diseases



### Neurology and Specialty



<sup>1</sup> Adjusted Revenue is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section 8 — Financial Results under Non-GAAP measures in the Management Analysis & Discussion for additional details.

<sup>2</sup> Trailing twelve months ended September 30, 2025.

\*The trademarks and logos of in-licensed products are typically owned by the respective partners. For example: MINJUVI, PEMAZYRE, ZYNYZ and NIKTIMVO, and their respective logos, are registered trademarks or trademarks of Incyte.

# Pipeline and Products in Early Launch Stage

Building for long-term growth over \$200M<sup>1</sup> peak potential sales

| PRODUCT                       | TERRITORY          |       |       |    |       | EXPECTED LAUNCH YEAR |           |
|-------------------------------|--------------------|-------|-------|----|-------|----------------------|-----------|
|                               | CA                 | BR    | AR    | CO | MX    |                      |           |
| <b>Oncology/Hematology</b>    |                    |       |       |    |       |                      |           |
| Minjuvi® (DLBCL) <sup>1</sup> |                    | Q1-24 | Q4-25 |    |       | Q1-25                | 2025-2026 |
| Minjuvi® (FL) <sup>2</sup>    |                    | ●     | ▲     |    | ▲     | ▲                    | 2027      |
| Retifanlimab                  |                    | ▲     | ▲     |    | ▲     | ▲                    | 2027-2029 |
| Axatilimab                    |                    | ▲     | ▲     |    |       | ▲                    | 2027-2029 |
| Pemazyre®                     |                    | Q4-25 | ■     |    |       | Q4-25                | 2025-2026 |
| Tavalisse®                    |                    | ●     | ●     |    | ●     | ■                    | 2026-2027 |
| Bapocil® <sup>3</sup>         |                    |       |       |    | ●     |                      | 2026      |
| Xetrane® <sup>3</sup>         |                    |       | Q2-19 |    | ●     |                      | 2029      |
| Rembre® <sup>3</sup>          |                    |       |       |    | Q1-22 |                      | —         |
| O501 <sup>3</sup>             |                    |       | ■     |    |       |                      | 2025      |
| O502 <sup>3</sup>             |                    |       | ■     |    |       |                      | 2025      |
| O503 <sup>3</sup>             |                    |       | ▲     |    |       |                      | 2027      |
| O401                          |                    | ◆     |       |    |       |                      | 2027-2028 |
| O402                          |                    | ◆     |       |    |       |                      | 2027-2028 |
| H403                          |                    | ◆     |       |    | ◆     |                      | 2027-2028 |
| H402                          |                    | ◆     |       |    | ◆     |                      | 2028-2029 |
| <b>Other Specialty</b>        |                    |       |       |    |       |                      |           |
| Imvexxy®                      | Q1-24              |       |       |    |       |                      | —         |
| Bijuva®                       | Q1-24              |       |       |    |       |                      | —         |
| Crexont®                      | ●                  | ▲     | ▲     |    | ▲     | ●                    | 2027-2028 |
| Qelbree®                      | ●                  |       |       |    |       |                      | 2027      |
| Jornay PM™                    | Q4-25              | ▲     |       |    |       | ▲                    | 2025-2028 |
| Xcopri®                       | Q1-24 <sup>4</sup> |       |       |    |       |                      | —         |
| Myfembree®                    | Q1-24 <sup>4</sup> |       |       |    |       |                      | —         |
| Orgovyx®                      | Q1-24 <sup>4</sup> |       |       |    |       |                      | —         |
| Wynzora®                      | ●                  |       |       |    |       |                      | 2026-2027 |
| Vibegron                      | ▲                  |       |       |    |       |                      | 2028      |
| C401 (Neurology)              |                    |       |       |    | ■     |                      | 2026      |

<sup>1</sup> Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

<sup>2</sup> Relapsed or refractory follicular lymphoma (FL).

<sup>3</sup> Products developed by Knight's internal BGx capabilities in Argentina. Unless otherwise noted in above table, these products are marketed in Argentina.

<sup>4</sup> Date refers to the date of launch by Paladin, or Sumitomo in partnership with Pfizer.

◆ Development: Products under development stage.

▲ Pre-registration: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.

● Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.

■ Approved: Approved by regulatory authorities but not yet commercially launched.

<sup>1</sup> This forward looking information is based on assumptions specific to the nature of the Company's activities with regard to annual revenue growth considering industry information, expected market share, pricing assumptions, actions of competitors, sales erosion rates after the end of patent or other intellectual property rights protection, the timing of the entry of generic competition, the expected results of tenders, among other variables.


# Our Partners\*



# Financial Highlights

Innovative Promoted products: 73% of TTM Q3-2025 sales, delivered growth of 14% & 3-year CAGR of 29%

## Adjusted Revenue<sup>1</sup> by Therapeutic Area



<sup>1</sup> Adjusted Revenues is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section 8 — Financial Results under Non-GAAP measures in the Management Analysis and Discussion for additional details.


<sup>2</sup> CAGR represents the compound annual growth rate which is calculated as  $(\text{Adjusted Revenue for TTM 2025} / \text{Adjusted Revenue for TTM 2020})^{(1/\text{number of years})} - 1$ .

<sup>3</sup> Trailing twelve months ended September 30, 2025

# Financial Highlights

Strong Adjusted EBITDA<sup>1</sup> and Operating Cash flows — Investing in Pipeline

## Adjusted EBITDA<sup>1</sup> and Cash Flow from Operations



<sup>1</sup> Adjusted EBITDA is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Adjusted EBITDA is defined as operating income or loss adjusted to exclude amortization and impairment of non-current assets, depreciation, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

<sup>2</sup> Trailing twelve months ended September 30, 2025



# Balance Sheet Highlights

*Healthy Balance Sheet with capacity for more acquisitions*

**\$95.6 M<sup>1</sup>**

Cash and  
Marketable  
Securities  
\$0.96/share

**\$94.5 M<sup>1</sup>**

Financial  
Assets<sup>2</sup>  
\$0.95/share

**\$96.5 M<sup>1</sup>**

Debt  
\$0.97/share

**\$766.8 M<sup>1</sup>**

Net Asset Value  
\$7.69/share

**1.52x<sup>1</sup>**

Debt to TTM  
Adjusted  
EBITDA<sup>3</sup>

**Credit Available**

Additional credit  
available: \$100 M  
+  
Accordion: \$135 M<sup>4</sup>

<sup>1</sup> As at September 30, 2025.

<sup>2</sup> Financial assets includes fund and equity investments and derivatives.

<sup>3</sup> Adjusted EBITDA is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section 8 — Financial Results under Non-GAAP measures in the Management Analysis and Discussion for additional details.


<sup>4</sup> Accordion feature on The Revolving Credit Facility for an additional USD \$100M, subject to acceptance by Lenders.



# Strategic Fund Investments

*Delivering healthy results and cash*

## FUND PERFORMANCE<sup>1</sup>



### Fund investments

- Invested to obtain preferential access to innovative products for Canadian market
- Financial returns have been attractive, but have not been as effective at generating product leads
- No longer investing into funds, beyond already committed capital<sup>4</sup>

| FMV of Funds by expected exit date as at September 30, 2025 | \$ <sup>1</sup> |
|---|-----------------|
| 1-3 years   | 54.1            |
| 4-5 years   | 17.5            |
| 5+ years  | 0.3             |
| <b>Total</b>  | <b>71.9</b>     |

<sup>1</sup> In millions of dollars

<sup>2</sup> Represents total value to paid-in ratio which is calculated as distributions received from the strategic funds and the residual value not yet realized relative to the contributed paid-in capital.


<sup>3</sup> Includes realized gains of \$91M and unrealized losses of \$37M.

<sup>4</sup> As at September 30, 2025, \$4.2M commitment was remaining.

# Capital Allocation

Over \$250M invested in NCIB or 31% of shares outstanding\*

## Capital Allocation



\*Since inception of NCIB, average buy back price at \$5.69



# Capital Structure

As at October 30, 2025

**\$578.9 M**

Market Capitalization<sup>1</sup>

**\$485.4 M**

Adjusted Enterprise Value<sup>2</sup>

**99.3 M**

Common Shares Outstanding

**7.0 M**

Stock Options and Share Awards<sup>4</sup>

**23%**

Insider Holdings %<sup>5</sup>

<sup>1</sup> Calculated using the share price of \$5.83 and shares outstanding 99,289,228 as at October 30, 2025.

<sup>2</sup> Enterprise value includes Knight's market capitalization adjusted for cash and marketable securities, debt and financial assets.

<sup>3</sup> Adjusted EBITDA multiple is calculated using Adjusted Enterprise Value as at October 30, 2025 divided by Adjusted EBITDA for the trailing twelve months. Adjusted EBITDA and Adjusted EBITDA multiple are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

<sup>4</sup> Share awards include performance, restricted and deferred share units as at October 30, 2025.

<sup>5</sup> Represents directors, officers and management team common shares holdings as a percentage of total common shares outstanding as at October 30, 2025.



# Management Team



**Samira Sakhia - Canada**  
*President and Chief Executive Officer*  
Paladin Labs, Chief Financial Officer  
Executed sale of Paladin Labs for over \$3 billion



**Monica Percario - Brazil**  
*Global VP Regulatory and Quality*  
Sanofi, Head of Regulatory and Center of Expertise LATAM  
Farmasa (now Hypera Pharma), Regulatory Affairs  
Extensive experience with >70 products approved across LATAM  
including innovative and generic products, biologics and  
nutraceuticals



**Amal Khouri - Canada**  
*Chief Business Officer*  
Novartis, Global Business Development and Licensing  
Paladin Labs, Business Development  
Led multiple regional and global product and M&A  
transactions of over \$1 billion



**Leopoldo Bosano - Argentina**  
*VP Manufacturing and Operations*  
Givaudan, Bristol Myers Squibb  
Led several manufacturing sites across LATAM including  
restructuring and supply chain optimization



**Arvind Utchanah, CPA - Uruguay**  
*Chief Financial Officer*  
Paladin Labs, Finance  
Ernst & Young, Audit  
Managed capital of \$1 billion and implemented financial  
and operational systems optimization in 11 countries



**Henrique Dias – Uruguay**  
*Global VP Marketing*  
AstraZeneca, Global Director Respiratory  
Janssen, LATAM Lead Hematology  
Launched multiple new products in different countries and  
geographies, managed business and products with sales over \$1  
billion worldwide



**Susan Emblem - Canada**  
*Global VP Human Resources*  
Paladin Labs, VP Human Resources and Corporate  
Communications  
Led integration of Paladin Labs with Endo International



**Melanie Groleau - Canada**  
*Global VP Medical and Clinical*  
Sanofi, Head of Business Planning in Commercial and Scientific Affairs  
Pharmacist with 25 years of experience in health care system and  
pharmaceutical industry



# Board of Directors



**Jonathan Ross Goodman**  
*Executive Chairman*  
Knight Therapeutics, Founder  
Paladin Labs, Co-founder, former President & CEO



**Robert N. Lande**  
Paladin Labs, Board member from 1995 to 2014  
Stratos Global International LLC, President



**James C. Gale**  
*Lead Director*  
Paladin Labs, Board member from 2008 to 2014  
Signet Healthcare Partners, Managing Director



**Michael J. Tremblay**  
Former President of Astellas Canada  
Former Chairman of Innovative Medicines Canada



**Samira Sakhia**  
Knight Therapeutics, President and CEO  
Paladin Labs, CFO from 2001 to 2015



**Janice Murray**  
Former President of Novartis Canada  
Former CFO of Novartis Latin America and Canada region



**Nicolás Sujoy**  
Clara Capital Partners, Founding Partner  
Former Director of Advent International

# Key Achievements - last 24 months

## New Products

- Acquired Paladin assets
- Licensed Sumitomo Canada assets
- Crexont® for Canada and Latin America
- Onicit® for Mexico, Brazil, and select LATAM countries
- Two branded generic products molecule in Oncology/Hematology (O401 and H403) for key territories in LATAM
- Zynyz® (retifanlimab) and Niktimvo™ (axatilimab) for Latin America

## New Launches

- Minjuvi® in Brazil, Mexico and Argentina
- Imvexxy® and Bijuva® in Canada
- Jornay PM™ in Canada
- Pemazyre® in Brazil and Mexico
- Re-launched Onicit® in Mexico and Brazil
- Re-launched Myfembree® and Orgovyx® in Canada

## New Submissions

- Tavalisse® for Brazil and Argentina
- Qelbree® for Canada
- Crexont® for Canada and Mexico
- Minjuvi® for follicular lymphoma for Brazil

## New Approvals

- Minjuvi® in Mexico and Argentina
- Jornay PM™ in Canada
- Tavalisse® in Mexico
- Pemazyre® in Brazil, Mexico and Argentina
- Rembre in Chile

## Performance TTM - Q3-25

- Revenue of \$414M
- Adjusted Revenue<sup>1</sup> of \$413M
- Adjusted EBITDA<sup>1</sup> of \$64M
- Ending cash, marketable securities and financial assets over \$190M

## 2025 Acquisitions

- Closed Paladin acquisition in Canada in June 2025 for \$85M, plus \$22M of inventory
- Sumitomo licensed products generated revenues of \$11.2M for the TTM ended March 2025

## 2025 Guidance

- Revenues of \$430M-\$440M
- Adjusted EBITDA<sup>1</sup> between 13.5% to 14.5% of revenues


<sup>1</sup> Adjusted Revenue and Adjusted EBITDA are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section 8 — Financial Results under Non-GAAP measures in the Management Analysis and Discussion for additional details.

# Why Knight – Great value in growing markets


Unique Platform in high growth markets

Profitable Business with strong Revenues, Adj. EBITDA and Cashflow


Strong Financial Position



### Balance Sheet Highlights



### Experienced Management Team



### Expanding Pipeline

| PRODUCT                       | TERRITORY          |       |       |       |       | EXPECTED LAUNCH YEAR |
|-------------------------------|--------------------|-------|-------|-------|-------|----------------------|
|                               | CA                 | BR    | AR    | CO    | MX    |                      |
| <b>Oncology/Hematology</b>    |                    |       |       |       |       |                      |
| Minjavi® (DLBCL) <sup>1</sup> |                    | Q1-24 | Q4-25 |       | Q1-25 | 2025-2026            |
| Minjavi® (FL) <sup>2</sup>    |                    |       |       |       |       | 2027                 |
| Relifanlimab                  |                    |       |       |       |       | 2027-2029            |
| Axatilimab                    |                    |       |       |       |       | 2027-2029            |
| Pemazyro®                     |                    | Q4-25 |       |       | Q4-25 | 2025-2026            |
| Tavalisse®                    |                    |       |       |       |       | 2026-2027            |
| Bapocicil <sup>3</sup>        |                    |       |       |       |       | 2026                 |
| Xelran® <sup>3</sup>          |                    |       | Q2-19 |       |       | 2029                 |
| Rembre® <sup>3</sup>          |                    |       |       | Q1-22 |       | 2025                 |
| OS01 <sup>3</sup>             |                    |       |       |       |       | 2025                 |
| OS02 <sup>3</sup>             |                    |       |       |       |       | 2027                 |
| OS03 <sup>3</sup>             |                    |       |       |       |       | 2027-2028            |
| Q401                          |                    |       |       |       |       | 2027-2028            |
| Q402                          |                    |       |       |       |       | 2027-2028            |
| H403                          |                    |       |       |       |       | 2027-2028            |
| H402                          |                    |       |       |       |       | 2028-2029            |
| <b>Other Specialty</b>        |                    |       |       |       |       |                      |
| Imvexxy®                      | Q1-24              |       |       |       |       | —                    |
| Bijuva®                       | Q1-24              |       |       |       |       | —                    |
| Croxent®                      |                    |       |       |       |       | 2027-2028            |
| Qelbree®                      |                    |       |       |       |       | 2027                 |
| Jornay PM <sup>TM</sup>       | Q4-25              |       |       |       |       | 2025-2028            |
| Xcopri®                       | Q1-24 <sup>4</sup> |       |       |       |       | —                    |
| Myfembree®                    | Q1-24 <sup>4</sup> |       |       |       |       | —                    |
| Orgovyx®                      | Q1-24 <sup>4</sup> |       |       |       |       | —                    |
| Wynzor®                       |                    |       |       |       |       | 2026-2027            |
| Vibegron                      |                    |       |       |       |       | 2028                 |
| C401 (Neurology)              |                    |       |       |       |       | 2026                 |

<sup>1</sup> Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).  
<sup>2</sup> Relapsed or refractory follicular lymphoma (FL).  
<sup>3</sup> Products developed by Knight's internal R&D capabilities in Argentina. Unless otherwise noted in above table, these products are marketed in Argentina.  
<sup>4</sup> Date refers to the date of launch by Paradin, or Sumitomo in partnership with Pfizer.  
 \* Development: Products under development stage.  
 † Pre-clinical: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.  
 ‡ Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.  
 § Approved: Approved by regulatory authorities but not yet commercially launched.



*Building a leading specialty pharmaceutical company*

**Knight Therapeutics Inc.**  
**(TSX: GUD)**